Andrew Rae

Mr. Rae is President and CEO of iCo Therapeutics, Inc., an ocular development company he co-founded in 2005. Andrew has spent a decade in the biotechnology industry, formerly as CFO with Ability Biomedical Corporation (Irvine CA, Vancouver BC), acquired by Medarex, Inc. in 2004. Mr. Rae has also served as Vice President, Finance & Corporate Affairs at Active Pass Pharmaceuticals (Vancouver BC). Mr. Rae has raised significant venture financing, engaged in a successful cross-border M&A transaction, and played a significant role in shaping multiple business development deals (Cambridge Antibody, Isis Pharmaceuticals, Medarex). Prior to his operational experiences, Mr. Rae served as Biotechnology Equities Analyst, Goepel Shields & Partners (now Raymond James Canada), covering Canadian biotechnology stocks including Angiotech Pharmaceuticals, QLT Inc. and ID Biomedical.

Mr. Rae currently sits on the BCIT/University of British Columbia BSc in Biotechnology, Honours program Program Advisory Committee, the Dean’s External Advisory Board for the Faculty of Business Administration at Simon Fraser University, the Board of Directors of Migenix, a biotechnology company in Vancouver, and the Board of Directors of Covenant House Vancouver, a charity operating shelters and counsel to homeless youth in Vancouver, BC. Mr. Rae’s degrees include a BSc from the University of Western Ontario and an MBA from Simon Fraser University.